TRB Advisors’s Verve Therapeutics VERV Stock Holding History

TRB Advisors’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-60,000	Closed	-$3.62M	–	13
2021 Q2	$3.62M	Buy	+60,000	New	+$2.49M	0.82%	11

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TRB Advisors's VERV Position: Q3 2021 in Review

TRB Advisors sold out of Verve Therapeutics (VERV) in Q3 2021, closing a stake of 60,000 shares — an estimated $3.62M sold.

TRB Advisors first reported a position in VERV in Q2 2021 and held it in 1 quarter. The position peaked at $3.62M in Q2 2021. 73 funds tracked by Wall St. Rank hold VERV as of Q3 2021.

TRB Advisors reported no remaining Verve Therapeutics position as of Q3 2021 after selling out during the quarter.
TRB Advisors sold 60,000 Verve Therapeutics shares in Q3 2021, an estimated $3.62M.
TRB Advisors first reported a position in Verve Therapeutics in Q2 2021 and held it in 1 quarter.
TRB Advisors's Verve Therapeutics position peaked at $3.62M in Q2 2021.
73 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2021.

Based on TRB Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.